Conduit Pharmaceuticals (NASDAQ:CDT – Get Free Report) and DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.
Earnings & Valuation
This table compares Conduit Pharmaceuticals and DiaMedica Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Conduit Pharmaceuticals | N/A | N/A | -$540,000.00 | N/A | N/A |
| DiaMedica Therapeutics | N/A | N/A | -$19.38 million | ($0.56) | -11.23 |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Conduit Pharmaceuticals | 0 | 0 | 0 | 1 | 4.00 |
| DiaMedica Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
DiaMedica Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 11.29%. Given DiaMedica Therapeutics’ higher possible upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Conduit Pharmaceuticals.
Profitability
This table compares Conduit Pharmaceuticals and DiaMedica Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Conduit Pharmaceuticals | N/A | N/A | -328.67% |
| DiaMedica Therapeutics | N/A | -43.67% | -40.81% |
Volatility and Risk
Conduit Pharmaceuticals has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.
Insider and Institutional Ownership
3.3% of Conduit Pharmaceuticals shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 30.9% of Conduit Pharmaceuticals shares are held by insiders. Comparatively, 7.2% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Conduit Pharmaceuticals beats DiaMedica Therapeutics on 6 of the 10 factors compared between the two stocks.
About Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Conduit Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conduit Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
